CellCentric Presents Positive Phase 2 Dose Optimization Data for Inobrodib in Multiple Myeloma at ASH Annual Meeting
United Kingdom and Boston, Massachusetts--(Newsfile Corp. - December 7, 2025) - CellCentric, a clinical-stage biotechnology company developing inobrodib as...
2025-12-07 8:00 AM EST
CellCentric to Host Investor Event and Present Dose Optimization Data from Phase 2 Study of Inobrodib for Multiple Myeloma at the American Society of Hematology (ASH) Annual Meeting
United Kingdom and Boston, Massachusetts--(Newsfile Corp. - November 3, 2025) - CellCentric, a clinical-stage biotechnology company developing inobrodib, a first-in-class, oral p300/CBP inhibitor for the...
2025-11-03 9:00 AM EST
CellCentric Announces Completion of Enrollment for Dose Optimization Cohorts in Phase 2 Study for Multiple Myeloma
United Kingdom and Boston, Massachusetts--(Newsfile Corp. - September 9, 2025) - CellCentric, a clinical-stage biotechnology company developing inobrodib, a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma (MM), today announced completion of patient enrollment in the randomized dose optimization portion of its Phase 1/2 clinical trial evaluating inobrodib in combination with standard doses of pomalidomide and dexamethasone (InoPd). "This achievement marks the...
2025-09-09 7:00 AM EDT
CellCentric Announces First Patients Dosed with Inobrodib in Combination with Bispecific Antibodies in Multiple Myeloma
United Kingdom and Boston, Massachusetts--(Newsfile Corp. - September 3, 2025) - CellCentric, a clinical-stage biotechnology company developing inobrodib, a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma (MM), today announced that it has initiated dosing in new cohorts evaluating inobrodib in combination with B-cell maturation antigen (BCMA)...
2025-09-03 7:00 AM EDT
CellCentric to Participate in Upcoming Investor Conferences
United Kingdom and Boston, Massachusetts--(Newsfile Corp. - August 5, 2025) - CellCentric, a privately held biotechnology company developing inobrodib, a first-in-class p300/CBP inhibitor for multiple myeloma, today announced that members of its senior management team will participate in several upcoming investor conferences.These events provide an opportunity to engage with the investment community and highlight the company's clinical progress with inobrodib, which will be entering a...
2025-08-05 9:28 AM EDT